Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore

Respiratory Medicine

Volumn 100, Issue 12, 2006, Pages 2190-2196

  Lee, Kang Hoe ^a   Phua, Jason ^a   Lim, Tow Keang ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

COPD; Pharmacoeconomic; Singapore; Tiotropium bromide

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG UTILIZATION; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGAPORE; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; SINGAPORE; TREATMENT OUTCOME;

EID: 33750849823     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.03.011     Document Type: Article

References (9)

1. Data from Singapore Ministry of Health website: www.moh.gov.sg.
2. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
3. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
4. Friedman M., Menjoge S.S., Anton S.F., and Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 22 (2004) 741-749
5. Oostenbrink J.B., Rutten-van Molken M.P., Al M.J., et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 23 (2004) 241-249
6. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper Jr. J.A., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
7. Vincken W., van Noord J.A., Greefhorst A.P., et al. Dutch/Belgian tiotropium study group. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
8. Friedman M., Serby C.W., Menjoge S.S., et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 115 (1999) 635-641
9. Benayoun S., Ernst P., and Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 119 (2001) 85-92